Twist Bioscience president sells shares to cover tax

Twist Bioscience Corp President and COO Patrick John Finn reported a mandated sale of 2,888 shares of common stock on August 3, 2026 at an average price of $85.3212 per share to cover tax withholding from vesting Restricted Stock Units.

Rhea-AI Filing Summary

Twist Bioscience Corp President and COO Patrick John Finn reported a mandated sale of 2,888 shares of common stock on August 3, 2026 at an average price of $85.3212 per share to cover tax withholding from vesting Restricted Stock Units. These shares were sold under a required “sell to cover” election and are not discretionary trades. After this transaction, he directly holds 269,678 shares of common stock.

Insider Trade Summary

Net Seller: 2,888 shares

Net Sell 1 txn

Insider Finn Patrick John

Role President and COO

Sold 2,888 shs ($246K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	2,888	$85.3212	$246K

Holdings After Transaction: Common Stock — 269,678 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Key Figures

Shares sold: 2,888 shares Sale price: $85.3212 per share Shares held after transaction: 269,678 shares

3 metrics

Shares sold 2,888 shares Common stock sold on August 3, 2026 to cover tax withholding from RSU vesting

Sale price $85.3212 per share Average price for the 2,888 shares sold in the sell-to-cover transaction

Shares held after transaction 269,678 shares Directly owned Twist Bioscience common stock after the reported sale

Key Terms

Restricted Stock Units, tax withholding obligations, sell to cover, equity incentive plans

4 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold by the Reporting Person to cover tax withholding obligations"

sell to cover financial

"funded by a "sell to cover" transaction and do not represent"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"Issuer's election under its equity incentive plans to require"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TWST executive Patrick John Finn report?

Patrick John Finn reported a sale of 2,888 shares of Twist Bioscience common stock on August 3, 2026. The shares were sold to cover tax withholding triggered by the vesting of Restricted Stock Units (RSUs).

How many Twist Bioscience (TWST) shares did Patrick John Finn sell and at what price?

He sold 2,888 shares of Twist Bioscience common stock at an average price of $85.3212 per share. This transaction was designated as a sell-to-cover for tax withholding obligations tied to RSU vesting.

Why did the TWST President and COO sell 2,888 shares?

The 2,888 shares were sold to cover tax withholding obligations arising from the vesting of Restricted Stock Units. The filing states these are mandated “sell to cover” transactions under the company’s equity incentive plans, not discretionary trades.

How many Twist Bioscience (TWST) shares does Patrick John Finn hold after this sale?

After the August 3, 2026 transaction, Patrick John Finn directly holds 269,678 shares of Twist Bioscience common stock. This figure reflects his post-transaction direct ownership as reported in the Form 4 data.

Was the TWST insider sale part of a discretionary trading plan?

The transaction is described as mandated to satisfy tax withholding via a “sell to cover” under Twist Bioscience’s equity incentive plans. The footnote specifies that these sales do not represent discretionary trades by the reporting person.

What type of shares were involved in the TWST insider transaction?

The transaction involved common stock of Twist Bioscience Corp, sold in connection with the vesting of Restricted Stock Units (RSUs). The sale funded required tax withholding owed upon the RSU vesting event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:06 PM Accepted by SEC EDGAR 08/05/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finn Patrick John

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S(1)		2,888	D	$85.3212	269,678	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)